The University of Oxford said on Wednesday that it is studying the anti-parasitic drug ivermectin, supported by the British government, as a potential treatment for the coronavirus. It aims to increase the rate of recovery of patients during home isolation. The results of laboratory studies showed that ivermectin decreased virus replication. The university said that giving the drug early can reduce the viral load and duration of symptoms in some patients with mild COVID-19.
A British study in January showed that the antibiotics azithromycin and doxycycline were generally ineffective against the early-stage COVID-19 virus. While the World Health Organization, European and American regulators recommended against the use of ivermectin on patients with corona. It was being used to treat disease in some countries including India.
Chris Butler, the co-principal investigator of the trial, said that by including ivermectin in a large-scale trial, we are hoping to generate strong evidence to determine how effective its treatment is against COVID-19 and its use. What are the side effects associated with it?
The university said patients with severe liver disease who take the blood-thinning drug warfarin or use ivermectin for other treatments would be excluded from the trial. The university said ivermectin is the seventh drug to be investigated in the trial and is currently being evaluated along with the antiviral drug favipiravir.